SRR23303762
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.590
- PROTEIN_SECRETION+0.540
- OXIDATIVE_PHOSPHORYLATION+0.450
- MYC_TARGETS_V1+0.420
- INTERFERON_GAMMA_RESPONSE+0.400
- DNA_REPAIR+0.310
- TGF_BETA_SIGNALING+0.310
- HEME_METABOLISM+0.220
- PI3K_AKT_MTOR_SIGNALING+0.220
- UNFOLDED_PROTEIN_RESPONSE+0.190
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- ANGIOGENESIS-0.400
- APICAL_SURFACE-0.400
- CHOLESTEROL_HOMEOSTASIS-0.390
- MYOGENESIS-0.390
- E2F_TARGETS-0.380
- KRAS_SIGNALING_DN-0.320
- COAGULATION-0.310
- HEDGEHOG_SIGNALING-0.310
- G2M_CHECKPOINT-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R337 | — | — | 0.827 |
| 2 | TCGA-4Z-AA89-01A-11R-A39I-07 | — | — | 0.809 |
| 3 | SRR12202456 | — | — | 0.796 |
| 4 | SRR8942997 | — | — | 0.776 |
| 5 | SRR23303735 | — | — | 0.775 |
| 6 | BS_KVAJYZ6F | Glial-neuronal tumor NOS | — | 0.773 |
| 7 | DRR168564 | — | — | 0.771 |
| 8 | SRR650201 | — | — | 0.769 |
| 9 | DRR168512 | — | — | 0.767 |
| 10 | MDT-AP-0026 | Med | Medulloblastoma | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.590 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.540 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.450 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.220 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.120 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.080 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.020 | Inavolisib | — uncovered |